Company / Operating Cash Flow
Twist Bioscience Corp Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$47.6M
FY2025
5-year range
-$142.5M / -$47.6M
FY2021-FY2025
Trend
+25.7%
vs FY2024
Sector context
#94 of 214
Health Care
What the data says
At -$48M, Twist Bioscience Corp's operating cash flow ranks #94 of 214 in the Health Care sector. Operating Cash Flow has fluctuated over the past 9 years, ranging from -$142M in FY2023 to -$48M in FY2025.
Based on SEC 10-K filings.
-$48M in FY2025.
Improved from -$142M to -$48M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#94 of 214 in Health CareTop 44% of 214This company -$47.6M Sector average $663.6M
▼
-107.2% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 25.7% year-over-year.
- Ranks #94 out of 214 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$47.6M | +25.7% |
| FY2024 | -$64.1M | +55.0% |
| FY2023 | -$142.5M | -14.5% |
| FY2022 | -$124.4M | -10.8% |
| FY2021 | -$112.2M | +21.1% |
| FY2020 | -$142.3M | -61.8% |
| FY2019 | -$87.9M | -32.9% |
| FY2018 | -$66.2M | -29.0% |
| FY2017 | -$51.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026